Ovarian Endometrioid Adenocarcinoma Suspended Phase 2 / 3 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Suspended2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02839707Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment